Lexeo Therapeutics Inc Net Income per Employee (LXEO), current and historic results, rankings and more, Quarterly Fundamentals - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Sales per Employee
• Income per Employee
• Inventory Turnover
• Asset Turnover
• Receivables Turnover
Lexeo Therapeutics Inc   (NASDAQ: LXEO)
 

Lexeo Therapeutics Inc Net Income per Employee

LXEO's Quarterly Results, Trends, Rankings, Statistics
Lexeo Therapeutics Inc recorded a cumulative net loss of $-87 million during 12 month ending in the second quarter 2026.
The Healthcare sector has seen employees of 112 other companies achieving higher income per employee. While income per employee total ranking has improved so far to 3923, from total ranking in previous quarter at 4606.


What is Income per Employee Ratio?





Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

LXEO Net Income per Employee (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Net Income Change - - - - -
Net Income per Employee (TTM) $ -1,479,068 -1,483,068 -1,694,254 -1,779,085 -1,935,119
LXEO's Total Ranking # 3923 # 4606 # 4169 # 4258 # 4279
Seq. Net Income Change - - - - -

LXEO Company Profile >> Back to LXEO Efficiency Comparisons >> Compare LXEO Net Income per Employee to its Competitors

LXEO Net Income per Employee Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 113
Healthcare Sector # 718
Overall Market # 3923

Net Income per Employee Statistics
High Average Low
$ -340,814 $ -1,442,422 $ -1,935,119
(Sep 30 2023)   (Jun 30 2025)




  News about Lexeo Therapeutics Inc Income per employee

Advancements in Gene Therapy Lexeo Therapeutics Reports Promising Interim Data for LX2006 in Friedreich Ataxia Cardio...

: Lexeo Therapeutics, a clinical-stage genetic medicine company, has announced positive interim results from its Phase 1/2 clinical trial for LX2006, a gene therapy targeting Friedreich ataxia (FA) cardiomyopathy. The interim data supports the advancement of LX2006 to a registrational study, and the company has planned a webcast to share further details. Friedreich ataxia is a genetically inherited disease characterized by progressive neurological and neuromuscular impairment, leading to significant cardiovascular complications, including cardiomyopathy. Current treatment options are limited, making innovative therapies such as gene therapy critical for affected patients. Lexeo Therapeutics is at the forefront of this therapeutic approach with its investigational drug LX2006, an adeno-associated virus (AAV) gene therapy designed to deliver the FXN gene, aimed at correcting the underlying genetic defect in FA.




Companies with similar Income per Employee for 12 month ending Jun 30 2026, within Healthcare Sector Income per Employee Income 12 month ending Jun 30 2026Number of Employees Jun 30 2026


Date modified: 2026-09-04T10:27:48+00:00




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.